0001654954-22-011401.txt : 20220815 0001654954-22-011401.hdr.sgml : 20220815 20220815181200 ACCESSION NUMBER: 0001654954-22-011401 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220815 DATE AS OF CHANGE: 20220815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zomedica Corp. CENTRAL INDEX KEY: 0001684144 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38298 FILM NUMBER: 221167481 BUSINESS ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: (734) 369-2555 MAIL ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: Zomedica Pharmaceuticals Corp. DATE OF NAME CHANGE: 20160908 8-K 1 zom_8k.htm FORM 8-K zom_8k.htm

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 15, 2022

 

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

 

Alberta, Canada

 

001-38298

 

N/A

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

100 Phoenix Drive, Suite 125, Ann Arbor, Michigan

 

48108

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (734) 369-2555

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, without par value

ZOM

NYSE American

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 15, 2022, Zomedica Corp. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 9.01 Exhibits.

 

(d) Exhibits

 

 

99.1

 

Press Release, dated August 15, 2022.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ZOMEDICA CORP.

    
Date: August 15, 2022By:

/s/ Ann Marie Cotter

 

 

Name: Ann Marie Cotter

 
  

Title: Chief Financial Officer

 

  

 
3

 

 

Exhibit Index

 

99.1 

 

Press Release, dated August 15, 2022.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
4

 

 EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm

 

EXHIBIT 99.1

 

 

HOLD FOR RELEASE UNTIL

4:01 pm ET, Monday August 15, 2022

 

Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million

of Revenue; 71% Gross Margin & $186.8 Million in Cash

Revenue up 51% from 2021 Combined Revenues

 

ANN ARBOR, Michigan, August 15, 2022 (ACCESSWIRE) – Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company, a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three and six month periods ended June 30, 2022. Amounts are presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

 

Larry Heaton, Zomedica’s Chief Executive Officer, commented: “The second quarter of 2022 was an exciting one for Zomedica as we both grew revenue organically and also executed on our acquisition strategy. We were pleased with our revenue growth to $4.2 million which reflects a  51% increase on a pro-forma basis, over the combined revenue of Zomedica and PulseVet as a standalone company of $2.8 million in the second quarter of last year.

 

“Sales of PulseVet products continued to grow during the most recent quarter, reflecting a 48% increase over the previous year’s second quarter sales by PulseVet as a standalone company. Twenty-two systems were sold for use with small animals during the quarter, a twentyfold increase over PulseVet’s second quarter 2021 small animal sales as a standalone company. As we further expand our field sales organization, we look forward to the continued growth of this segment.

 

“During the second quarter we also continued to build the installed base of our TRUFORMA® diagnostic platform through our ‘Customer Appreciation Program’, under which we provide veterinarians with an instrument at no cost to them in exchange for a commitment to utilize our assays. We are preparing to launch the Free T4 assay in the second half of 2022, completing our thyroid disease panel, and we continue to work with our development partner to produce assays for non-infectious GI disease for launch in 2023. To drive customer education and interest, our marketing team continues to sponsor presentations by luminaries in the field introducing new assays at veterinarian conferences throughout 2022.

 

“We’re very pleased that we were able to bring to fruition several of our M&A initiatives. During the second quarter we closed on our $1 million investment in Structured Monitoring Products (SMP), the maker of the VetGuardianTM wireless pet monitoring system. We have begun collaborating with SMP on completion of product development and integration with the myZomedica portal with an eye towards Zomedica beginning commercialization in early 2023.

 

“Following the quarter, we closed on the purchase of the assets of Revo2’s imaging products and Assisi Animal Health’s Assisi LOOP® and Calmer Canine product lines. These acquisitions add to the Zomedica portfolio of products that improve the quality of care of the animals being treated and the satisfaction of their owners in addition to significantly improving the workflow, cashflow and profitability of veterinarian practices.

 

“The Revo2 MicroView® is the first and only digital microscopy platform that provides fully automated slide preparation, designed to dramatically improve veterinarian practice workflow as well as to reduce the number of unreadable images due to faulty slide preparation. The combined Revo2/Zomedica team is further enhancing the product and integrating it with the myZomedica portal with a plan to launch in the first half of 2023.

 

 
1

 

 

“The Assisi LOOP® and Calmer Canine products previously sold by Assisi Animal Health are now offered by Zomedica through various channels, including directly to veterinarians through animal health distributors, through Zomedica’s websites (https://assisianimalhealth.com), and online retailers such as Amazon.com and Walmart.com.

 

“As we grow revenue from our existing products and integrate the recent acquisitions, we also continue to evaluate strategic business development and M&A options in the large and growing animal health sector to identify potential new opportunities.”

 

Second Quarter 2022 Financial Highlights

 

-

Total revenue for the second quarter 2022 was $4.2 million, compared to $16,000 in the second quarter of 2021. Gross margin was 71%.

 

 

-

Total revenues of $4.2 million were up 51% over the combined revenues of Zomedica and PulseVet as a standalone company in the second quarter of 2021 of $2.8 million.

 

 

-

TRUFORMA® product revenue was $92,000 in the second quarter of 2022, an increase of 486% over second quarter 2021 revenue of $16,000.

 

 

-

PulseVet® revenue was $4.2 million in the second quarter 2022, an increase of 48% over its second quarter 2021 revenue of $2.8 million as a standalone company.

 

 

-

PulseVet unit sales to Small Animal Veterinarians totaled 22, a twenty-fold increase over its second quarter 2021 Small Animal Veterinarian sales as a standalone company, of 1 unit.

 

 

-

Zomedica ended the quarter with cash and cash equivalents of $186.8 million, reflecting use of $5.5 million of cash during the quarter, including its purchase of a $1 million convertible note from Structured Medical Products, makers of the VetGuardian product.

 

Summary Second Quarter 2022 Results

 

Zomedica reported a net loss for the three months ended June 30, 2022, of $5.3 million, or $.005 per share, compared to a net loss of $4.7 million, or $0.005 per share, for the three months ended June 30, 2021, an increase in losses of approximately $0.6 million, or 14%.

 

Zomedica reported a net loss for the six months ended June 30, 2022, of $ $9.2 million, or $0.009 per share, compared to a net loss of $8.7 million, or $0.044 per share, after adjustments for equity charges for the six months ended June 30, 2021, an increase in losses of approximately $0.5 million, or 6%.

 

Revenue for the three months ended June 30, 2022, was $4.2 million, compared to $16,000 for the three months ended June 30, 2021, an increase of $4.2 million or 26,438%.

 

The increase was primarily due to the inclusion of our PulseVet platform which had revenues of $4.2 million consisting of instruments, trodes, and warranty services sold worldwide. Revenues from sales of cartridges from our TRUFORMA platform were $92,000 compared to $16,000, an increase of $76,000 or 475%.

 

Revenue for the six months ended June 30, 2022, was $8.0 million compared to $30,000 for the six months ended June 30, 2021, an increase of $8.0 million or 26,557%. The increase was primarily due to the inclusion of our PulseVet platform which had revenues of $7.8 million, consisting of instruments, trodes, and warranty services sold worldwide. Revenues from sales of cartridges from our TRUFORMA® platform were $148,000 compared to $30,000, an increase of $118,000 or 393%.

 

 
2

 

 

We launched our TRUFORMA platform in March 2021 and acquired PulseVet in October 2021. In general, we expect revenue to increase in subsequent periods as we increase our sales and marketing of the PulseVet platform and as additional assays are added to our TRUFORMA platform.

 

Cost of revenue for the three months ended June 30, 2022, was $1.2 million compared to $36,000 for the three months ended June 30, 2021, an increase of $1.1 million or 3,261%. Cost of revenue primarily resulted from costs associated with sales of our PulseVet platform which totaled $1.1 million, as well as $75,000 from costs associated with sales of our TRUFORMA platform.

 

Cost of revenue for the six months ended June 30, 2022, was $2.2 million compared to $42,000 for the six months ended June 30, 2021, an increase of $2.1 million or 5,136%. Cost of revenue primarily resulted from costs associated with sales of our PulseVet platform which totaled $2.1 million as well as $120,000 from costs associated with sales of our TRUFORMA platform.

 

We anticipate that costs of revenue will increase in 2022 in accordance with the increased revenue as described above.

 

Research and development expense for the three months ended June 30, 2022, was $319,000 compared to $271,000 for the three months ended June 30, 2021, an increase of $48,000 or 18%. The increase was primarily driven by an increase in contracted expenses for research fees and trials as we continue to develop and test our next generation of TRUFORMA assays.

 

Research and development expense for the six months ended June 30, 2022, was $670,000 compared to $684,000 for the six months ended June 30, 2021, a decrease of $14,000 or 2%. The decrease was the result of a reduction in research and development activity associated with TRUFORMA as we completed development of the instrument and three of the first five assays and began commercialization in March of 2021.

 

Selling, general, and administrative expense for the three months ended June 30, 2022, was $8.6 million compared to $5.0 million for the three months ended June 30, 2021, an increase of $3.5 million or 71%. The increase was primarily driven by salaries and stock option expense associated with increased hiring campaigns and the inclusion of PulseVet headcount, PulseVet acquisition related intangible amortization, and an increase in consultant fees for market development and research and specific accounting and internal control work.

 

Selling, general, and administrative expense for the six months ended June 30, 2022, was $15.3 million compared to $8.5 million for the six months ended June 30, 2021, an increase of $6.8 million or 80%. The increase was primarily driven by salaries and stock option expense associated with increased hiring campaigns and the inclusion of PulseVet headcount, PulseVet acquisition related intangible amortization, increases in office expense, travel and tradeshow attendance/sponsorships associated with a lifting of COVID restrictions, our TRUFORMA launch, and marketing of our new line of PulseVet products.

 

Liquidity and Outstanding Share Capital

 

Zomedica had cash and cash equivalents of $186.8 million as of June 30, 2021, compared to $276.2 million as of June 30, 2021. The decrease in cash is mainly a result of the cash flows from financing activities, partially offset by cash flows used in operating and investing activities as discussed below.

 

As of June 30, 2022, Zomedica had shareholders’ equity of $266.2 million.

 

 
3

 

 

Net cash used in operating activities for the six months ended June 30, 2022, was $6.5 million compared to $4.4 million for the six months ended June 30, 2021, an increase in cash used of $2.1 million, or 49%. The increase in cash used in operations primarily resulted from the increase in our operating loss. In addition, cash used in operations during the six months ended June 30, 2022, included increased salary expenses and inventory purchases, offset in part by an increase in non-cash expenses including stock-based compensation expense and depreciation and amortization.

 

Net cash used in investing activities for the six months ended June 30, 2022, was $1.6 million, compared to $142,000 for the six months ended June 30, 2021, an increase of $1.5 million, or 1,057%. Cash used in investing activities during the six months ended June 30, 2022, included a note receivable of $1 million and expenditures to improve our ecommerce, internal sales, and accounting programs as well as for leasehold improvements.

 

Net cash provided by financing activities for the six months ended June 30, 2022, was $0, compared to $218.7 million for the six months ended June 30, 2021, a 100% decrease. Cash from financing activities in 2021 primarily resulted from proceeds from the February 2021 public offering of our common shares, partially offset by stock issuance costs.

 

As of June 30, 2022, Zomedica had an unlimited number of authorized common shares with 979,899,668 common shares issued and outstanding. As of August 15, 2022, Zomedica had 979,949,668 common shares issued and outstanding.

 

For complete financial results, please see Zomedica’s filings on EDGAR and SEDAR or visit the Zomedica website at www.zomedica.com.

 

For additional information regarding our products, please click on the Products tab at the top of the home page on the Zomedica website (www.zomedica.com).

 

About Zomedica

 

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

 

Follow Zomedica

 

 

·

 Email Alerts: http://investors.zomedica.com

 

·

 LinkedIn: https://www.linkedin.com/company/zomedica

 

·

 Facebook: https://m.facebook.com/zomedica

 

·

 Twitter: https://twitter.com/zomedica

 

·

 Instagram: https://www.instagram.com/zomedica_inc
     

Reader Advisory

Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

 

 
4

 

 

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions  with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

 

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

 

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Investor Relations Contact:

PCG Advisory

Kirin Smith, President

ksmith@pcgadvisory.com

+1 646.823.8656

 

 
5

 

 EX-101.SCH 3 zom-20220815.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zom-20220815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 zom-20220815_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 zom-20220815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 zom-20220815_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 zom_ex991img1.jpg begin 644 zom_ex991img1.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 15, 2022
Cover [Abstract]  
Entity Registrant Name ZOMEDICA CORP.
Entity Central Index Key 0001684144
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Aug. 15, 2022
Entity File Number 001-38298
Entity Incorporation State Country Code Z4
Entity Address Address Line 1 100 Phoenix Drive
Entity Address Address Line 2 Suite 125
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Postal Zip Code 48108
City Area Code 734
Local Phone Number 369-2555
Security 12b Title Common Shares, without par value
Trading Symbol ZOM
Security Exchange Name NYSEAMER
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
XML 10 zom_8k_htm.xml IDEA: XBRL DOCUMENT 0001684144 2022-08-15 2022-08-15 iso4217:USD shares iso4217:USD shares 0001684144 false 8-K 2022-08-15 ZOMEDICA CORP. Z4 001-38298 100 Phoenix Drive Suite 125 Ann Arbor MI 48108 734 369-2555 false false false false false Common Shares, without par value ZOM NYSEAMER EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://zomedica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. zom_8k.htm zom_8k.htm zom-20220815.xsd zom-20220815_cal.xml zom-20220815_def.xml zom-20220815_lab.xml zom-20220815_pre.xml zom_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zom_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "zom-20220815_cal.xml" ] }, "definitionLink": { "local": [ "zom-20220815_def.xml" ] }, "inline": { "local": [ "zom_8k.htm" ] }, "labelLink": { "local": [ "zom-20220815_lab.xml" ] }, "presentationLink": { "local": [ "zom-20220815_pre.xml" ] }, "schema": { "local": [ "zom-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zom", "nsuri": "http://zomedica.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://zomedica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001654954-22-011401-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-22-011401-xbrl.zip M4$L#!!0 ( 'R1#U4(@,T]B@0 (H6 0 >F]M+3(P,C(P.#$U+GAS M9,U8RV[C-A3=%^@_L-JT!2K)LI$@-IP,\I@! F12()D6V14,1=M$95(E*3_F MZWM)O1W)D>0L)BO2]YS[UB69^:?=.D(;*A43_-()O)&#*"\W6 %+<,L!85!([D ?$@M$C&9+'5WXP9D_'HW' M!>A9+/062XJP)"NF*=&)Q!$*J6)+CL!QE 8T0]>_$G2WPG*-8TG7F)N@T/5& M>X6N6Q'O)5NN-/J-_(Z,&73O/G[^AFX2Q3A5"CV+*#&NJ#_0/2<>NHXB]&08 M"CU11>6&AIDZ159@!$&&N9KMHDMGI74\\_WM=NOM7F7D";F$2$83_^6!\7^= M#"GIHA5Z[H,T!Y)$2BC6OD!;I*+$6XJ-GTMMKG(*5'2)<>QBK0O6 JM7JS\3 M^B"4[#714.>,IAAI-@*"FGZZ(ZMFI)'4H(QOJ-+-X%0&\&#BC@)W$N0D3I>F MPUKS,_6EB*B?P0H69D0U6[*BPQ3I?4Q58WZLI 97.I8MN0%)%5IS>CO)70[\ MEZ\/S[95G*)7H!V:X,%T.O6M-(>^0=8;RXA?X>LJ-(.4'<$S;KYT4L.'!T7* MP&=^*JQ!62/T/(6RHG%%PK5LZ]M46*^)ED=*#M*B&E*W5:\0U32'6AX0:OI! M[!NQX8Q,*XZ#JBG3;"VFK*ANBK+FB$%0 _)D_8XW@*"2D8(@> >.X.X!#_QL M=+YI9+2/BRKXNRC=@#4-&<$>$6L+&ET$9PXJILL7(==W=(&3"+Q(^'\)CMB" MF:^61M2<)S5 1:RQ7%+]B-=4Q9C0=PS")$9SS+G0]@0Q6]C',>,+83=H;KZ2 MF2G8-T@4,HN_GNZ;U=KQB='&-U'YI--_V%*,KNY M"K@%O-'R9GZ"$A%3J1E\I.60]#\DI B_]@T)*#3Z$6.!1NH;RT'O_6@109?W MC:C^87QT0'._,HU@4QM5V,0=8K]_N MNYFO>G>#+,BV$NM#VG M.N6_P-O5P K8VW8V[^ >2+1+=W$$SV@MY/X+[+LE(I*RIN5SJ>2DLC2\_[JZ M4V5]F \]TI$S3NJ)ZENV4U.4A'0YH8:+_ZCAQJW^HX=116GZ5MCKS'M'LUH.SE_S>ZU3W'V]6 S,.#LW_AJZ_4 M-/FYFF$>]"]]HP<]J]_P.A_:=X.BKCST3PC:_NNQ;G_NI_JN_@=02P,$% M @ ?)$/54J_W8C> 0 D@, !0 !Z;VTM,C R,C X,35?8V%L+GAM;(U3 M2X^;,!"^5^I_F-)#6ZG&D&BE!(5=Y;&'2-D>DK;:J]<,P:JQ(]N$9']];;+0 MC=I*RP%AYGO-,,SN3K6$(QHKM,JC-$XB0,5U(=0^CQI+F.5"1& =4P636F$> MG=%&=[?OW\T^$/*XV&Y@I7E3HW*P-,@<%M *5T$H/3#KT!#R@OYY\?'_@!ZUL M=K(BCRKG#AFE;=O&[3C69N_[25+Z^+#9\E90^1X\Q[>-XN!69[>PVFG?#?0,-_HL()]+#2'A%TA$9I_')%I&?!L!E M'D9+W&()$!Y^;->#Z;.NL1"I7@_=943K@ 3BY7"N3/ MS_#J,:S@O?+8LU^94OOU"T$N"6?T:DUN?P-02P,$% @ ?)$/5:UQ4J!]<&F<,"5L*5$$IWS#HTA&S0/QN? ?32?IJ==L^OF/4L MK2+'%_.N[US*V806"&E\(A=[5A$@JT8J[ M!X>FH0&,/G"X*9FIV,)@Q51H"D9+EW9:UWKQ9,2\=/"1?X)@ [?DZY?O<%5; MH=!:N->R#E'L9[A5/(61E# )# L3M&B66&SDI%"_!N%OZOL#/VAE!VLKADGI MW&) Z6JU2E?]5)NY[R?+Z?=K&Z91]M7 =81M\0INBAUHQL#'96//X'E[A "\BPAUI820\(GF/]/-T M;8O$#PZ@&9W1$BEO76$A.$NYKF@HTFOMU[ /&GFEP=DP\2 2 MWE]VFI\$Y?<[&/>T\$O9BFHA_2SHEJM?1*WQ/NBVQ0L=MH,+K376I9M[H0RJLIN%% M'Q1VEWKLI$S*P_)%PK%3*>U&AP9K.?]Q+>*,U=+]\V)LZ=N)_4.A1-C8QOYV M)S6N':H"BS9WD'OM1N2$"^"L^>5 _AZ5!"(2OK$Y^G-DIOV9%/R;_:_-)37? M"2/#]JO-\QG:MGF+/)WK)2U0Q$,R7,1ML)DBBL?H.YI:9QAWK9)D4Y11_]%C M-DUL)D3WC"@<;W3G?+OX U!+ P04 " !\D0]56!1\9O4% !@-P % M 'IO;2TR,#(R,#@Q-5]L86(N>&ULS5M=;]LV%'T?L/]PYSUL R8K=K"A,9H6 MKIL6P9P/Q.E6;!@*6:)M8A)ID'1L__N1U$$!,8XI.>\-^B<]0"2D$2;+\]Z&>P$/,>X!%P&)@I@2=-[;(]Y[^^;[ M[U[_X'F?W]U-X3T--PDB B8,!0)%L,5B!6KH*N ",<_+T'^F\XQ@V#_MG[PJ MSK\+N&11HCER<%",O)?Q@"X@5)$U]>25/_C-'YX,AP5H1A=B&S $ 0M76*!0 M;%@00X0X7A*0PB%-: 3CGT)XOPI8$JP92@*BDH+Q@^@7L29TO6=XN1+P<_@+ MJ&G@TKN^N(=W&XX)XAQF--XH*?Q7N"1A'\9Q#'>*P>$.<<0>4)2%BS'Y;Z1^ MS&5^(!>:\-&.X_/>2HCUR/>WVVU_>]JG;"GS.1GXGZ^FLW E=7F8J 4/42]G MJ2@FWN#L[,S7HSFTAMS-69S/<>KGGP1S%/5#(3W>7UJS.2K$RDO]$J<\+?HL8IM$%R6?Y M2HE6PSY5_%>=?B8")EZTY'6^XP3NJ0CB%TD_9#H6?8U>MMJ//->K++L^>MDJ M'S"_@6A1%_SLI36M::Q.3>5122#:"40B%.4258"&CJOCZ\:N(Q>Q:5B*&JO> M35D];RZCZH@<\&"4.21=!+G/<.X M7Q:D<&.6JY*WX".)90@_I/(&MQ9>?-@2%XPFQDFSG*EA\$L\+_CIHL@IC#)+ M((8XW; 0/:L>AUIM*Y3I26*)4+LH1+Q/L]X;C8%_,2" K?@A8GW--B!\IKT M5.M;8$"!6FCG%PEB2TR6'QG=BM6$)NN V)NZ!>VRM3<*+C=X([0#QCBNSM+L MM36T-PJ.+\/*1@D&A2\A4[R M I/,$;-:_A#BLF?4I94;Q>-X!\IOD61I"0H'*;"%FE^2D+(U9?HQ\$Q( MXTWH1FY(]Q,:V3\G'F&Y=,:3$BB;I9'2&?\\1:7%4B4J:"YD9%#L%GPVCB*Y M1#S[-<4$#:R9&[$N/=4@MNPD [ S_K%KL[@F0Q:_%04&G?#*\!E9#MOVRO"I M7AEVV"O#%WAEV)Y7)O+PAMW3+3F6XR&R!9_4A1I=\@CKFD=JRHXX1.'AAH%B MM.,/F 2VCFL8:%P;ST=F*-PP:;G!<'Z/16RZINL0-S6W2H$?8CI0_ 99U@L]Q[I_&^8O.;] 9$*39$-P^B(T-V1EP;EQ M0Z/(W Y&4 ?\T*2K:H@,"V6PV^9 8QQB(5O3E?SHR7!@]+@!Y*@Q6.45;:&& MZ( )K*)J+:$ 0HYT6OY;AI3YD"R"?J='O;/+;A8+XW:_">S&#L?EYK:P(SM@ MCZ/BJC:1!#AD0$H!S6G3,)><;Q![EFT,E%;,8Y5NL5 -WSTCV20>M5-*;';5 MX8FI/%+_\Y6=PNG_0;WY'U!+ P04 " !\D0]5!X&F#'X$ #](@ % M 'IO;2TR,#(R,#@Q-5]P&ULS9I=<^(V%(;O.]/_H-*+MC,UQF33)DRR M.X2P.YG-!P-IN].;'2$?0%-98B01H+^^1^9C(=A&>U&TN2!@OY+.^^A8Z-A< MO5MD@KR -ES)ZUI2;]0(2*92+L?7M9F)J&&^86^R-J1)CK.6_:N(B3\[C9:#:WHH$:V3G50*AF$VZ!V9FF M@J1@^%@2#)RL#+5(^R=&;B=49W2J(:/2F2+M%UO?]M51TZ7FXXDE/[-?B!N& MW$6/W6=R,S-<@C%DH,3,A6)^)7>2U4E;"-)W+0SI@P'] NFZ.\'E/RWW,D1_ M!$%+TUH8?EV;6#MMQ?%\/J_/S^I*C]%/(XD_/=P/V 3CBKATP!G4-JU<+T7M MDLO+RS@_NY$>*!=#+39CG,6;<%!N>,ODP]TKEL/U:$9*%>Y3M)%%[E"4-*.S MI+XP:0UI$++BH96 /HR(^_]'_VX[YK\J@Y0S6F"'S_FX[:&QFC*[Z4G0(8B\_\^H>26)__>8 MNA)1+?LPYFY,:1]I!L6A%2OW(]R=S[9F1.D4-$[#ID=<"/9F\3!=UXIXBNN& MM!&N&V*; ".MLC)2:R[J2+B[^'"HTQ'NH!M<_.XPH1%EY) MO5"?!UP?"JT%R.WW7,#C+!M^V7H5)?2NR@OM;\&R^-!0 *I8P"@]53K',D Z MT%$S_)9==E1:N3T[TM"+_>_!V'O9#C =[31%5&;]#PL52*HFH5#NA?XB&/H* MB]\$\.;7 6]Z K_\AH WPP/OX-LG_:SFT@/WKMBO1 E7!Y;Z"\=$^K M%[ZZI70,^$$+/^KA*L-JI^'0]Y2Q5/S-I\>^3HOU?MA#5(_'79X4NKO9]A1_8$*5DD9.3HG3W@D5OHF3E;OM0Y8_3%2C^V(%V]/@IAAPAYT_0'#/3O73:%2V5ZC2^ST> M"5'.'7<9$OJ=,3/07XN^H)7?!(2H['P='TS#57S@Y1X/N!]DK,ZX%_[YF. OKOK+V^$+4!78_LD.8'[Z]^N;!,; M3""Y?+;I3":QM=J5]DN[*\EM_#*;NN2*"L Y-[+O?8[Q][GPL+ M<)4/?P-J*D$].?+%E"H8!6*J&J6R47Z?0F)(9F<0P7-Q[%]MQ'-H'%@)'CL4 M F8W7R#2HTDP):W0L5R.NV1(7A_HD5M'1T?F#%F2X)U)G@=8+I4L\_>SSWU[ MPJ;4X)Y4U+/9HA<,_-MZ MB:@*Y IMA>.C"Q>4CE#69HY;? KXP$6AV5Y4H, M7#6CQ@PHSP5]'X'R!-1A/)_1T)#F<U%!]_;HH_O M&4O]!!NMY-?AG'BVR!V3Y&V8%0QAPSG!/W#&96*"<-H-J9,48)T#/97R*^. M"VW?4]##&,!,"\2.GHX+BLV4&1FZV6R8$>FA[\R)5'.710 &=?G8J[ELI.HC MZ%FS2H$BBD^9)!Z[)L*?4@\&[O"KN-N.PV7@TCGJ,:MOC:.^0[ASO(-3.>G^ M=Z?9X+,:#HF)Z$_N.,S3?P+>\TCSB4>G,$ZPN%K' Q;-VS Q0=VNY[#9KVP> M3W:F>F@:IT '68U>TZHJ_^;O0K,$SNS]8<6J5!IFAL1ZBBV0@H.2.'7I>&M* M)/+@QP7P^K6A#[9#O1%UP;LU]:\5\F9V\F#&#/TXD\T&.L::U.X7R!+M4VNH MSL<[DD\#E^W$[R;H&G9 GXQ$U8HSZ0"/S2R*B%J:A'Z4?BCTD_:\M7BF**Y; M>1J#,RV9Y(D[^#SB3!!-EN4N>^WNKUF9+'=N)J^RV /@F>\D3[ ,"'4"1M*\ M&5;2[Z9M,4QG#6C2DCPG1,P,.Q(\H<]*4 M/&/_%5S]"04QK*"+IZ(;[X0/Z%\NX00#!O:F(;4*4N6+>\YBI3^^/&&>/^5> M'MIM9Y-!869'GYFTF=5>,^513.C0; 2)ISN].!\8_>[73HV@;ZH3_>*T==;] M_$=MQ5.1LU;O4_>\1DK!K$Y2'LX&;62B7FC^_)/UOE1OF 'X]$XZ/>/CQ6!P<58CU6!&I.]R M!TC FH ZJ.%OZU/.[V/&]$P]OH=GA7;V"2-2['@ .C<_W,MG?T,JX7OCYI?S M[J!S0OJ#UJ#3;YCQVZ?$ ;#>5))]V0 ?5RK/(P4(7FZ47O MC*Q=]Y, +!5-;1%@'!J_KB[M.(CF=\YIT/Q>YWQ >IW+B][@.Y_L92AD2"$X M5S[I,QL3=6(=$%\0J[KK[!%_1 83ADVAX(H#Q<[,GE!OS$C+5MAL'1U4OG,F M83"%4^VQP!>*[";/C,+2S:0B[ KS&Z&;F;-76_!CLU%>ZMBL$T5L]PO*'>@Y MA7X3A\[G,"8&Z4TK'(0 M;@K7GS!Z/IK7IU2,N6?@XERCH?*3%X*/)_&;*"AY#S$)L9GK!M2)JF6E=(R2 M#&'"=$<+ I/"+3'(3R7]CUB+6"2B/ MC;G$TIPZAY;MUX.O%V>=DVZ[!3% [[*XU=*0#O@V">!E\)=-F[N=&07/AFQ# M&Q<+=A$JB0R8C>F<0[A'N)($?"&8O-AKF-!U:=)/&K$^K;4=5I_"V@Y*+\+: M6NX0!D'WUSOSR+*ZGNT+6 )TN;NOP"NWH])AVW?NY]JQREYCSIB*0/A7<2$2 MW7N;>M2A.4:X;'W+!E9]EV'?DDKHQQ&=6^9=I JU$HHRI7)+5%Z79#<( M])2[#-I ^G>IRUG&P6'YZ/!-./]0..=FZ_[+R7,O(MK\,8SVU80)\B=$S]+A M.KY>6BKPY_%$_MQ\:/O3*9?R1YMVM]L M[<,@"Z9].?&9QV?D1/"KE6W"C='T*OGR]N3[(8?EURI7[TNV#7]>B(%_[6U/ MM.5YI"5 />]+5 <-%^(28GVNCX/<-V60B A3!B2$^<(9MR=\3+WED9$MHE*K M]#+"TE=E-9<^R,#]RH,[Y7[-RJ%5VB9S>!U!Q&[,#*RC! )4F@?4)6S&[%"! M2X#7L-8P^4.ML;N@$P25XEF6UF,._A# MH!K%J'Z$,E6E#0&/(-2;)VTCWP7BV ]71(ZYJ"2[DC'RB7E,@$?J>M WC#:_ M6L5R,1HN;N,\B63N%-VFCF#\@T U7E$W+JCW\KYI-;EE.^(WP15('2L$H1?G M'/+^,0\>31M2$#4P02\ 1Q\JE7KNQM>SKPA)7E)HQDR 6:>Y0(+4MFPO!.VH ME*NQ9JOL=BSNPNY:'TC[M$?*!Z4B .X]=)SPF%K0APC/AJEXXS-P%N QW!]- M!6XX0*8Q"U;E;U6H8953*I#9AE\H0*54C"!?E0Y<"H9> $]PZG,JN!2(B]'H M#LOL=Z(+P G#3K%BHU^P*HY1WAWN;:<9$>QKUHVNE"$3;QIR!PTY8$9EU]Y. M0V+890UY^HK?$T2K70_O,V" .B>VCEQ!.;^1ZPG36S9+824$J=0CP'+4WS$9 M"_]:39#Y 8::5!*'C;@7'0R(5NQ2-8E EY;KZ-#4 =G%^7ZHZU4[ >;Z2$& M1PIP]RB28'EHE'-PY9W$6B!%:=[T2Z$M?@?YAJ[; KG.&G%LJ-$DW3[I7NVH MTY,XDM?-]L1P1K>8 F;QN7;%5S*U"5@-C:&4M36YR80&&_9.50X,LH$ M$7^0>_YQE^XE]I8VLB)9R/:UR+).!IW?!T;W_*1S/JB12C6?:,JK1 )B8AUS M=+01,P=X\B*3Y+@]VMY9K2?'S4-?*7^:T_XP.79 [S$%YUTM<'"72KE+07\5SU3077AL3^?#GUW5^X]VCS?/^L\S^-C MC5J@+/%M8-?7$PYO;HS_SCG"/V/.,?DU^)_B4AR)W.:Z\>(P4L MR7;P^1_]#FEI>JM[PL^>^SWD!<0UEPGO<;E4CS-S_635]PC'XI]#**1O>*I 0/)( M(6&DG@<9'MJ=3DI2O?0^\TTJ*&(Q8 J)D'^%^O(&B5+-_X0>(P>E:%Q%T@)/ M&RPV$;,4.> (A#E9@)'W)%CHZ*%IE ^ 0)$TI7[VPFIRBC+U\LOE6@ MX;CWBLHQ6PH9[PMR;_'='RR(Z0+4PASV-6\R/*-*04 *'(J8MX^<&S*4:(K/ MT$E.J.OJ8L&0$8@P\08$;F<#KD;8=*XJ4K(%.-]0I!TQD/7_5*S3+ M#4O04;%D)>8F7^?JLDH!+R 7XABLZ,C"S\256BB[V^8]+;#IX]T]O3QYG2I(X5> M%"GL:T?I+$<]Q>RDUX?*.:(:Z7^%AYG$8S#F*7#>B6,YROT8&]IXZ+WR0DZQ MWI->VP>\Y!+7Z"Y6)ZBMS^F>4$6)OA2SRZ9#YCAQ/*$C&03%3S[J;[HMHH[G MWT%^K>GY4C%BZ((^IPM9*^E[7DVI_);1/^QYZ<6'D;J?SEN#+[U'^#K3BTG@ MTM^$B;9L_PJYT.F%W#IURMGK=4*(Z6T:XOZLSH#BS"<*VB6, !K\Z+L*0P;I MT A#E\++Q787R.@*^#,Z'92-NJ]1N9^1= M]">KC0O1#MY"M(<.T5(?Q=( M#K/CVF--1Q"8IA2:2>%9?W-Y\=VJ%Q([?'_UG63Z;U6>MRK/6Y7GK#DY,2YH=&WM/6MWVS:6?P7K36;2L[)L^?VJSZJ.DWHWCK.VV\[T MRQR(A"34),$!2,O*K]][+P 2I"0_DCBMG7QH:ILD'A?W_<+!N$B3PX.QX/'A M02&+1!Q^5.F_Q,WN;J\+SPY6[!\/_F-Y^;6*RE1D!8NTX(6(66ED-F+'K]_V MST^Y*81>7CX\6+%C#50\9::8)N+'I^\-]=MH_ M?WL"4ZSF-_NL$#?%,D_D*-NC*9<._Y8-3+[/#E;R0_;%Y]!R-,9)#DRA538Z M//['SR<_G5RRW=UN[V#%_?%QIFYLSTY1\$$B_#0#I6,X&I/S"(YK;W4_^/:/ MTA1R.-T?JJS8FW<<^RG7(YDMXR1[O"R4_P-MV/YE(N-B#%^OOEQBD4B2G,P;.1'02J3Z=[\)>VMXC ' M,ATQHZ,?ERJTA;_TNG_DH_HP/&B"8P"\CK_8&MRX/Y^]>PUG>,[.C]\=]R^. MV2_O+T_>+3K]SYSL #_P8T4J47I/BWCI<&-OMIL=MK:ZMG:P@I\>SH(#_M'X#R+/(^!I!*Q#Z!:F/MHD%9Q$>OB[2D4L(\[Z M6:;*+(*A+D0$P&'_5W(-[Q-PD'-Q+;)2[+/MWDOV5BMCV"GA!?L;3X&OO>CM;'5WJJ7"WX^X M&?]Y2W;K967.-F'%0Q@#P=QC1RH=R S$AWO#?(TESF&2CS2%AT'__7O6/__I M[!SH4$9C.>)99Y84W3\^,?V-_^MUP-15=:H>Z1TWCU8 M*>'5]_\$WM)/A8:_9WN_GYW^P%[A)VNK^_YU^A5&4)JY)P#UG&?3#N/L6L!I M :[K*0-9G11C%MF'@.]#?#)BN9+ CM1P.>):L%CR4:9 4D2&<:":8BPTST4) M?V"Y5G$9 :T,82X[#J(?_)ORQ'28%KG2J"P O1F5R)@TAV%%:MJ1&GX.X\)_ M6@B:Q<@;E@*G&K,<%J5BPT06P[?_4V:"K:]:"'8!$$#2, N-(?1$!=!-8%7 M->-1A ]I1["O2.8)G.5(9+#^))GBIH^L[K@$/?@:%3@%^AOC3V]XW[&@LQ9 =WX@(3OM:L+/A M4$9"=_"H4P+UGL>P2P"@L6SUWXZM @2)LTXX(@X3-Y&DPU!P@GC@%7;#\XE@ M P6'/=*X=L<\E :R@1?HL&!@0"D%P^!JX)P SU2)I_SO4AH8&7X'>H*S&TV[ M[#'DB87!\W8\]TFH"?RJ4Y?&I8YR3,5 KO#1,!*(U9_80D(YJPC6=BL5^?TR.PN PB['$)8Z093P73'U=GU@+^ 88E0-A!V4,B'1 M"2<)!Y D\.>0X'QY_@O8#J?] U-6ZX:3+I#[N?GAB= X?V][ PU9^/VP MELW Z7B!# EEJ"I'EML1@FSM'X': 1Q(LWX.& ^2E[CE!ZU&FJ<.B3I.:EH. M.$':4-)(0MZ M'UX"<9* \6,9N#%\:HAE.RF>T-:@:7&_;U%DL<\V3HQ0T) M)V#[5M242.=3K60,>HPA"@+<%DF'./&DQE><;:+T52TI8F#?B MH1Q#$F[9M+M,9%HB$_>*'XZN+TPP\=*P+YE54*\!>0#6]A+F /V=T< MY?+4,A- ?2V T1M0N0M4OOUT5I01A8XY(.Y C$K$DB3A P4:%[Y#9 .KP1UY M L3-#;T$;]"3Q_.1MGA/7],NII6JA)8#0-@S'#'%HT!18VIU"E8BLPSG)XU4 MHU'A)!3Q(*Y!=;1D]TP0]PU 74UFE(4&1I%F4VK@OU; X.] ZL+Z-,#P5G_CN[.S#?:6:PT,<^H@G MR!J/0./(1(5#"?P"E 7&!NPLT/QA.7&E@C0P"+0GJ0(T-);"98KB37@@)K(@ MM9L,7@\QIYL-!$';>;V=!0PJ42'-D$<>R^%O$LAO E*"F"YZ0>D9\FG8J!RB MO5X .MJI_0FBS!G"B8+8XF:,/]$4\,I0%GP@_ MHE=%JU^EF#P0MZ1Q\E ;RX94!F<2RY%$9I/BJ"92^334IWCAE2&0]R59HR5( M;L('DZ".9)46IQG#:S"[U?MB4+!XX6Q8CW1SS[+"!&L.H^I.0EX+4C=PT5F9 M#BR/+S- QYC$$Q*F0 N")-60EPD@S,RJB&9JT_1!L%ZI"(I4$&EJ0R$;HR/' MH;(GT@9SAV>RN)N_([BS0..KU!8\ID"]6_]Z&'][&&5QS.23 R+ P8%+PX-\ M,-;U6KQO_O9OW8.?SLY?'Y\O_W1V>7EVNL<&"8^N6"^_8>1]VV=A,,XY;NW? M3MZ_/L:H' )FZ;!WSVGK<-W?V %34"[_'LKQ'#[>.U- M/UY XD_A<8\@$TWEQ .0WX&, #F"6:RKC+@+^3G%?1>3=G.:+P&IH0V#-IN M8":9#GH>DA(1&)@DV(XHP8!,FT:A_]HY&YQ?&8R@0LL!L$IM.M4[,T[&B1B M$ >(OCHH#\=%D9N]E15.&[#CV>&ZP+S0 _Y#Q[-M!((6!9<)REQ3 ML EME/ M^4?@=_ VO?<;P QT)/S]N0A+ZZPA%YAW,5)\!0T)<0- G]'3/#>V8L3YR4+U MJ3/CM5$1M@U!]-A+8V[RT@E5M]S#'PA.N1=>CC>LD5U\ 1 M,(P*178U"*P,H]$@%PK\"=Y!R*@);H]#_@S,,4$& M:?[".03T[6,(0_? #K#QK6XMEKEB]Y69W5U=7%@ !W 717B4ZE;D:\>P MOJ/=\T,[%[)P 0EO_7GN1AQL=^U./K76L>$$']\:LHV=+8>I\\):0535L<'O MN/7L<*L.&F(6&'T?5'0]#O6/5>L8VANN* W M:%L7%$AWMO2O3<,712](4<(W%Z]?GA.P7X1S"X>^/6#?023MT3*_H^&S0\-* M#;,9;T&O"Y:@[=C,RZ1\S+F) MF!V'6.LUXL&7+[JKJYN8O\G,&$S7I@T;S&(MENWFMZOMC^^YEEY3\H.&@'-8 M X?G@%\W$B,WR12GV&K,V=MX^?3CQ/I4\CN+;[ 099V^ILK.\\?4!?4OJ>VR?",-> 5UIB -EZS&V"'XA-XX0K M^N3K7%8?4K8Y=F,>+_;:8,*\<^7#HSK;#B,I(".%<1EL7&N>8<17Z&O,"+ A MH(G223R1L>A6=196+!N?8!N!3-,R'OD'81)BL%#T'7DK?@Z.S![]ML4=./6- M[IJBZPV-[=?VM#^8^+E=JA0 M_IF(^<"8:0N->QL[LWALCV06UKW>CD?D]=WUKXC(WW+:P=KWM(,O-\5OPB73 MB'@!=P<]Z92#56=]$51A@S%A)(V*-\ [9U&A!LYCT64GF2^AHJ"QN,E%X/7% M0&Z@AIER8$"AHQ1J5\9EBWUJ6BM]@07.7V<[.]MPED?1,DV57\>3*HL9$W;C MV-+UW T_>6ETA#GV )EV!/&>&E^OH5^$3/!S%;Y>MQ=*IO7.VE8/!%-[O;5< MLH5_6 N(/!YK!Q SC,+:!%^N58F$VX25]\"%2^B$*70OMC?MYNXYT;>#-??2 M9=86X3"[7N_MSNJK:]N]SS7.*\6VMW.'\8!E2AGF";:\*Y@DAFG+ M,)G;FW74: ^!H7 "'51YS*&W0C_,+7/PL2\))'J@I Q@ZK0+GU=?$9W'EK>W461;9V-A[&FF$=H2S?\/BQYM"C>HQSV@Q"Y,4V$D#YZ;[@1B_: M'>:X7Z-?K\U)@_.U*$*E0Z+YM5,&PYI#*L- U'?/;*;X$.OJO#X(KPS$B.K9 MYM0&62 Q4X+X*#LC;&VJ2@ ?*@VE7CR].%C MUN\DG%M,$A: <%86E#6"8+C :!L[XCE6N#V;1DM5F!.]U0_(B$ ] _[8HMZ6 MBKT5&+USWF]I1$Q[?LT%__[M#_QL=M6B!J?U+O#8K)%7L"B]3V* M^QHHF -"\0H?*^@LG"!(?[L+;C8K3L2!VD4JV[1VA7B^G!4*.XNXQ#E46BQ? MA[F1U\]QK& G&2O#_%AU$A[I@LL#FA'/"I[SIEY(-G?0X(_+*S@P% MS)5^#[,"PARP9H;#9WJX>ZU,HUYGE:+U1W=NX%.PD=O<2ZSM!.4')0ZMH59C M,N>K U(HM4UL]OT(J'#4.4E$IS8DRE MK(#G@W.N!0353<]3X!Z&=ZMMI;,7),P]P'6'^D&EBCKD6JAC.C=];R%#A3U& M0L2F9J]OQ$"7R-WL=^4@D5'=*=296(@[V!0)%; %BJRU9*4Q)44&*)SPY''C M;IT4F$*9)3*ESJ)U_PY>%F.EY4?+RFO86>-W=WNWL[.[V]G:VFD]1OBY)C2J M-O&H?Q_V*VWVEVTM!4?=W7C J$_]=-ZXGK3H3Y[M.=MQ+;^8$6*V*<%0HM?) M8#3B93+H?W2/?N.!9P#-(NY 9 M]3]UGJ(1)O"[CGMYE>CO0!P!T[CRG:FJYF6@D2.XR&NL8+\]O_%GX[/YB3NMIY_!?QILX; [=G7.K1;7C'I<2W-K M[VJZE*+1]P)%:*Q&QOF%"FJ,.%21O;;"X5:9I2">,A)YF'L(1$^E*HWV)MU9 M]N"+7>L.8SXZ>G;IBF%C8K$@*KHLT!PL!&V+F\!5Z_=WV M;"LPUR#*]4%A)P5"8V9-*;!QUW!L?NM.W'#=3F/:R-5R&W(Q.M>NHX[UCV6" M;?\*:H>+"9U./?4]TFP=IM340*W+D%. W2%"'M%Q7',.\5)G\Z>.W)YV;8.^ M/Y%X_WJM.[Y$4=R<.L.OU2*D<=E&^)&9I@.54-+QSOI^=;/&?2L%CU,N$]9/ MX)G98Z[YT=[*BK4)E38S$NYKU7G>"NXG!N5W,KL2\4E601C;2R$'2NB!I%91 M*TZ.K'RLR/8[M#\%VF]X) 9*736@G7:'[L\$Z^\P_CP87X*12([Q ,2%_=MW M^'X!^)Y@AW9T<S\&S4OIZ==1 M18YO\%854K\-WJ22^CCL6*)0(^47^^9V[+4 ,+#!1 -K)\)!<0 RZ!L:?V!+ M[G:!9;QJ@"K1:X5R*;C?IOU:/;._"^<5MJO&0OAKD4P[B[X+AO=WO)!+QO49 M207/G-N+YSD8M5;5$E&IK7\MX1/2?A<-2LU3M:V(2&R1*Z916D\0V"<3A>VM M?2O#)6R*NM1A2[;( G\"/?T/]R.Z:;,8?QJ(1(*FCC_6:;OT'=@=6/BZ9'T[ MU+/52* 1KNU4Y)@.CLFF^CK@H_*/1X=>E"QV?9:74CXER"^AQ0,_11'V\*>( MAS5^@N$H@<2U3K?="7$?+N92^PR&);JDO6.F"RI1,:9>D7@KC-V;71F>06L, MZFY0W^%SRX%2@0A:.RK#8Z.NZ1IC\QE,@C<8<&-*3=Y)FHQ.H3$;V7BN;[3" MCR*EL24F=4:'<3)5L%')L>Y-B-:N.E@ 0VO!"="3 G:O\$YR=@3C>[3P*T/J MP/Z_87O_&@Z -V5P@Y(;+K:+' C7I#HE?SX8<"JA65WHB2HD ,CD_L+ M /Q> _1LKML%4YPM2N7M29-'4AW,&93RB'.S( M)HU9Z5'%U<,P8F>V&3Z(,2KJJWK&NLM3?+\7;),_@$-R3-7>.N.C2#9-FX&2 M)82K*J8[8NKM )K3U3%E[N[.J%K2HK1T[CZL(O)IL&((("R"7$B 5%14>87+ MO5W6&JE3<]4LO*VN$H-/WM%\AE<[W4X;IAS\X7"44UMH8?.HM#17%C!XER9I M"H5/5[4:!B*"TEZ94&6"B%2:2F35>H4',]:#2(PI,J0Y;6.'+@2I3%B,=!]! MWV47&$-P\81ZO7>LKBYLN'M!0 +PJKF?WN$4HP[@5^&:<.--%C8F6*B] )!3 MU_1_,A:TV)"0'(Q;Z$[B?DJW^]3:$67]96((E+X_9W2*N,#\+H50U_>=AHGG M=!L2/@NE5F^Z@PL=EB) "&G)Q!RQ[1Q;PID9/ M\D)$XTPE:D3H$T1V[+6<5DT>-N*)^S;OJ;#9Z42./D6]?H4@@^O"KQL9+YG MU> 4L _,U"4KATR7^;?!--;K^UCL,WNOF0UZ^$TXX-5/P!(T#N\)_A8SVGB MEJ-'1K>>6FY:ZPF^PPSY_8;]\*5E;$U$/K(%\Y3(*FTJ4C#8ON.HN<5(9]W! M;ZETD *[6&2&BC:00LCL1KX/0^-'2#=#'-5J5#1:QPT:&HP-+*XB<[Z@,%N$ MV;,#60UE*!R&"]1W>*WM-!6ITLR@W:)MP \%W?F6-685U45$E7Z!URD*U.T( MV9#@K0XRJ\,$.8G51;7A\;00*"3 D$>*U@8\N5L1B(NMY" FBMN;HUP"I4]] MJ(IW+XZ/G+SW6$2W$R44H;X%C,F>8SRD:QKJO<3U.]!W(PY7E?_#.J$+^_0%YP7S"L7;2>9-%[] M !%"W&HHK?>(WG7 1C97&2?DH*#C*_@5^3KBTB)0F9,IXVZ=O4N3*>A^"*JE M)^](ZUG+)6'O=0AXXHP+2%A?(998(&).I!$UR0^FBYQLP/%,XE2]^7B&&(1< M"6QPVGB)XR;2"I7LK^'D>&3G[XF+(@*$G!A!)U,!9[3'OHXG^,/1V\KW_+CE M%O^+=6_L B00V,T? /](2WE<,)>'5P8G_.\\&G&WRSI.RQ\7M/_58UL;6]V= MM?7NSM;F5FNNSXK@L.\NN,T_Q0EV,%#Q]/#_ 5!+ 0(4 Q0 ( 'R1#U4( M@,T]B@0 (H6 0 " 0 !Z;VTM,C R,C X,34N>'-D M4$L! A0#% @ ?)$/54J_W8C> 0 D@, !0 ( !N 0 M 'IO;2TR,#(R,#@Q-5]C86PN>&UL4$L! A0#% @ ?)$/5&UL4$L! M A0#% @ ?)$/55@4?&;U!0 8#< !0 ( !C@D 'IO M;2TR,#(R,#@Q-5]L86(N>&UL4$L! A0#% @ ?)$/50>!I@Q^! _2( M !0 ( !M0\ 'IO;2TR,#(R,#@Q-5]P&UL4$L! A0# M% @ ?)$/50*"$TD%#P N68 H ( !910 'IO;5\X M:RYH=&U02P$"% ,4 " !\D0]5M -CK9D: "3AP #0 I@ &2(P >F]M7V5X.3DQ+FAT;5!+!08 !P ' +D! !6/@ ! end